Optima, a Global Phase III Study in Newly Diagnosed Primary Liver Cancer Patients
Ovation, a Study of Gene-mediated Immuno-therapy in 1st line Ovarian Cancer
LAWRENCEVILLE, N.J., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that Mr. Michael H. Tardugno, Chairman and CEO and Mr. Jeffrey W. Church, Sr. Vice President and CFO will be providing updates on its two promising investigational products being evaluated in Phase III, II, and I trials at the following upcoming investor conferences, respectively:
- The Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 10:50 a.m. Eastern Time at the Lotte New York Palace Hotel in New York City.
- The 2016 Aegis Capital Growth Conference on Thursday, September 22, 2016 at 9:30 a.m. Pacific Time at the Wynn Las Vegas.
A copy of the presentations can be accessed under "Financial Events" in the Investors section of the Company's website at http://investor.celsion.com/events.cfm.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas™ and TheraSilence™. For more information on Celsion, visit our website: http://www.celsion.com (CLSN-FIN).
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 email@example.com